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Abstract
Introduction
Pyroptosis is a regulated form of cell death, which is often a consequence of the activation of
inflammatory caspases. Appropriate inflammatory responses and the induction of pyroptosis
enhance the clearance of pathogens and increase innate immunity. However, excessive pyroptosis
contributes to a hyperinflammatory response and aggravates tissue damage, thereby causing
inflammatory diseases. There have been reports on the modulation of pyroptosis by statins, which
may explain part of the pleiotropic actions of these drugs in inflammatory diseases and cancer.
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Abstract 
Pyroptosis is a regulated form of cell death, which is often a consequence of the activation of 
inflammatory caspases. Appropriate inflammatory responses and the induction of pyroptosis 
enhance the clearance of pathogens and increase innate immunity. However, excessive pyroptosis 
contributes to a hyperinflammatory response and aggravates tissue damage, thereby causing 
inflammatory diseases. There have been recent reports on the modulation of pyroptosis by statins, 
which may explain part of the pleiotropic actions of these drugs in inflammatory diseases and 
cancer. Herein, the extant evidence for the potential value of statins in targeting pyroptosis in 
various diseases is reviewed. 
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Multiple forms of cell death may occur in response to various environmental stresses, particularly 
oxidative stress. Loss of control of cell death (in various forms) causes many human diseases such 
as cancer, autoimmune diseases, neurodegeneration, and infectious diseases (1). Classically, cell 
death is categorized into regulated cell death (RCD) known as apoptosis, and premature cell death, 
which is known as necrosis. In recent studies, a growing number of non-apoptotic modes of RCD 
have been discovered. These include pyroptosis, autophagy, netosis, and ferroptosis. According to 
the recommendations of the Nomenclature Committee on Cell Death (NCCD) 2018, pyroptosis is 
a regulated form of cell death characterized by the generation of membrane pores mediated by the 
gasdermin (GSDM) protein family, often but not always as a consequence of the activation of 
inflammatory caspases (2). It seems that pyroptosis shares morphological properties with both 
apoptotic and necrotic cell death. The plasma membranes of pyroptotic cells swell and rupture, 
and DNA fragmentation occurs (as demonstrated by positive TUNEL staining) similar to 
apoptosis. However, mitochondrial integrity is preserved, and cytochrome c is not released (3). 
Pyroptosis can be distinguised from apoptotic pathways of cell death by several features including 
the release of inflammatory cytokines such as interleukin (IL)-1β and IL-18. Pyroptosis can be 
induced by caspase-1 and caspase-4/-5 in humans, whereas classical apoptotic caspases are not 
involved. Despite the occurrence of nuclear fragmentation in pyroptosis, this is not as prominent 
as that detected in apoptosis (4).  
Caspases are essential for initiating apoptosis and pyroptosis. Caspase-1 is one of several 
inflammatory caspases which have important roles in the innate immune response. There are two 
distinct pathways for pyroptosis. These are triggered by different caspases. Caspase-1 is activated 
by the canonical inflammasomes and caspase-11 (human caspase-4/-5) is activated by non-
canonical inflammasomes (3). In both pathways, inflammasomes are primed and the expression of 
pro-IL1β and pro-IL18 levels is enhanced via activation of pattern-recognition receptors (PRR) 
(4). Inflammasomes are cytoplasmic protein complexes, which form families of PRRs (such as the 
subfamily of NOD-like receptors (NLRs)), inflammatory caspases, and in some cases an adaptor 
protein. They can be activated by endogenous and exogenous stimuli acting as a molecular signal 
platform for enzymatic activation of caspases and the subsequent inflammatory response (2). The 
subsequent mechanisms differ between the two pathways. In the canonical pathway, activated 
caspase-1 catalyzes the maturation of cytokines pro-IL-1β and pro-IL-18 into their active forms 
and results in pyroptosis. However, activated caspase-11 triggers pyroptosis directly in the 
noncanonical pathway. Activated caspase-1 is indirectly required for the production of IL1β and 
IL18 in the noncanonical pathway (4). It has been demonstrated that cell rupture and the release 
of proinflammatory mediators in the extracellular space amplifies the inflammatory response and 
exacerbates the injury caused by initiation of the cascade. Activation of caspases occurs in 
response to a variety of stimuli, which are identified by distinct inflammasomes. The key factors 
contributing to the activation of the NLRP3 (NLR family pyrin domain containing 3) 
inflammasome (the most extensively studied inflammasome), include reactive oxygen species, 
lysosomal membrane disruption, and ion efflux (including Ca2+ mobilization and K+ efflux). In 
addition, microRNAs (miRNAs) have recently been shown as a key regulator of the NLRP3 
inflammasome (2).  
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Appropriate inflammatory responses and the induction of pyroptosis enhance the clearance of 
pathogens and increase innate immunity. However, excessive pyroptosis contributes to a 
hyperinflammatory response and aggravates tissue damage, thereby causing inflammatory 
diseases. A great deal of evidence shows that some drugs or compounds which inhibit pyroptosis 
may be effective for treatment of various inflammatory diseases. In this regard, it is tempting to 
speculate that statins could be good candidates.  The efficacy of statins is well established in the 
prevention of cardiovascular diseases. They reduce circulating concentrations of cholesterol by 
inhibiting 3-hydroxy-3- methylglutaryl-CoA (HMG-CoA) reductase, the rate-limiting enzyme of 
the mevalonate pathway of cholesterol synthesis. In addition to their well-documented lipid-
lowering effects, there is a widely held view that statins exert many pleiotropic effects including 
anti-inflammatory, anticoagulant and immune-modulatory effects (5-9). Moreover, many studies 
have demonstrated the anticarcinogenic effect of statins in several models, including carcinoma of 
the prostate, colon and rectum, liver, lung, breast, and skin. There is evidence that statins are 
associated with cell death and apoptosis (4, 10). However, the mechanisms which mediate these 
effects remain poorly understood, but may involve reductions of downstream products of the 
mevalonate pathway including dolichols, isoprenoid intermediates, heme A and coenzyme Q10 
(11).  
Recent studies provide evidence for the potential value of statins in targeting pyroptosis in various 
diseases. For example, activation of the NLRP3 inflammasome and myocardial pyroptosis induced 
cardiac injury occur following coronary microembolization (CME). Chen et al. revealed an anti-
pyroptotic role of rosuvastatin in CME-induced cardiac dysfunction mediated via reduction of 
mitochondrial damage and ROS production. Rosuvastatin exerted an inhibitory effect on the 
NLRP3 inflammasome pathway and suppressed the expression of cleaved-caspase-1, IL-1β, and 
GSDMD-N (12). It was found that targeting of the inflammasome was a promising approach for 
the management of ulcerative colitis. Rosuvastatin treatment effectively reduced Ox-LDL-induced 
TXNIP (thioredoxin interacting protein) and thus attenuated the inflammatory response via 
NLRP3 inflammasome inhibition (13). Wang et al. reported that atorvastatin inhibited pyroptosis 
in vascular endothelial cells (ECs) by upregulation of the long noncoding RNA (lncRNA) NEXN-
AS1 and its neighboring gene NEXN. Expression of NEXN-AS1 has been shown to be reduced in 
human atherosclerotic plaques. Both mRNA and protein expression levels of canonical 
inflammasome pathway biomarkers including caspase-1, IL-1β, IL-18, and NLRP3 were 
decreased by atorvastatin, which then decreased inflammation and the progression of 
atherosclerosis (10). Metastasis-related lung adenocarcinoma transcript 1 (MALAT1) is another 
lncRNA that has been shown to be associated with pyroptosis. Upregulation of MALAT1 
evidently attenuated H2O2-induced pyroptosis in human umbilical vein endothelial cells, causing 
NRF2 (nuclear factor-erythroid factor 2-related factor 2) stabilization and activation. Atorvastatin 
was found to decrease renal oxidative stress and podocyte pyroptosis under conditions of high 
glucose. This occurred via the  MALAT1/miR-200c/ NRF2 axis (14). Atorvastatin has also been 
reported to improve early brain injury (EBI) after subarachnoid hemorrhage (SAH) by inhibition 
of neural pyroptosis and neuroinflammation through the ASC/AIM2 inflammatory pathway (15). 
In addition to the beneficial effects of statins on cardiovascular health, their anticancer properties 
have recently received increasing interest. There is some evidence that using statins improved 
survival in patients with lung cancer whether used before or after diagnosis. It was demonstrated 
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that simvastatin induced pyroptosis in a xenograft mouse model and in non-small cell lung cancer 
(NSCLC) cell lines. Thus simvastatin treatment attenuated the viability and migration of tumor 
cells without causing toxicity to normal lung cells (4). In conclusion, pharmacological activation 
of pyroptosis in cancer is beneficial, whereas inhibition of pyroptosis in inflammatory conditions 
can ameliorate disease. The most recent literature describes putative roles for statins in the 
regulation of pyroptosis. As shown in Figure 1, statins can contribute to inhibition of pyroptosis 
through canonical inflammasome pathway. In addition, it seems that interference with oxidative 
stress is the prominent mechanism of the regulation of pyroptosis by statins. These findings have 
important implications for the development of new treatment strategies in a range of diseases. 
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Figure 1. Molecular mechanism underpinning therapeutic regulation of pyroptosis by statins. 
NLRP3; NLR family pyrin domain containing 3, ASC; Apoptosis-associated speck-like protein 
containing a caspase recruitment domain, AIM2; Absent in melanoma 2, TXNIP; Thioredoxin 
Interacting Protein, NRF2; Nuclear factor-erythroid factor 2-related factor 2, NEXN; Nexilin F-
Actin Binding Protein, IL-1β; Interleukin-1β, IL-18; Interleukin-18 
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